Navigation Links
Data Presented at Society for Neuro-Oncology Annual Meeting Demonstrate Tocagen's Toca 511 Gene Therapy with Toca FC was Well Tolerated and Showed Antitumor Activity in Patients with High Grade Glioma
Date:11/26/2013

groups. Since radiation therapy and temozolomide are part of standard therapy for patients with newly diagnosed GBM, these data provide support for clinical investigation of Toca 511 and Toca FC in first line therapy.

"I am pleased with the progress we have made with our clinical programs, and the available survival data provide optimism for subsequent dose groups in these studies," said Harry Gruber, M.D., CEO of Tocagen. "The results from our ongoing clinical studies, taken together with the depth of our preclinical research, provide momentum for the continued investigation of this novel gene therapy for patients with brain cancer."

Data from preclinical brain cancer studies also presented at the conference demonstrate the feasibility of intravenous administration of Toca 511 as a potential complement to the current intra-tumoral delivery methods. An investigational trial was recently initiated to evaluate intravenous delivery of Toca 511 in combination with courses of oral Toca FC in patients with recurrent HGG (NCT01985256). In the future, Toca 511 may be investigated for the treatment of additional types of cancers beyond brain cancer, including metastatic cancers.

About Toca 511 and Toca FC

The combination of Toca 511 (vocimagene amiretrorepvec) for injection and Toca FC (flucytosine) extended-release tablets, is being investigated in Phase I studies at leading centers across the United States in patients with recurrent high grade glioma, including glioblastoma multiforme (GBM). Toca 511 is a retroviral replicating vector (RRV) that is designed to deliver a prodrug activator gene called cytosine deaminase (CD) selectively to cancer cells. After allowing time for Toca 511 to spread through the tumor, those cancer cells expressing the CD gene can convert the antibiotic drug flucytosine into the a
'/>"/>

SOURCE Tocagen Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
4. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
7. CutisPharma Homogeneity and Stability Study for Mouthwash Compounding Kits Presented at NERDG Meeting
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
10. Body Monitors Deliver Better Weight Loss Results at Half the Cost: Study to Be Presented at ACSM Meeting
11. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... FALLS CHURCH, Va., April 19, 2011 Technology Catalysts ... announced that research on cancer trends and development has ... a variety of cancers that currently have ineffective treatments. ... is forecast to approach $3 billion in 2015. ...
... April 19, 2011 Symmetry Medical Inc. (NYSE: ... to the global orthopaedic device industry and other medical ... its operations in a matrix structure to strengthen quality ... businesses will now report directly to Thomas J. Sullivan, ...
Cached Medicine Technology:Cancer Vaccines Poised to Reach $3 Billion in Sales by 2015 2Cancer Vaccines Poised to Reach $3 Billion in Sales by 2015 3Symmetry Medical Centralizes Businesses Under CEO 2Symmetry Medical Centralizes Businesses Under CEO 3Symmetry Medical Centralizes Businesses Under CEO 4
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on ... review today examining the current state of knowledge of ... for improved global surveillance strategies to combat the emergence ... Ebola in West Africa that has claimed the lives ... Liberia. According to the World Health Organization (WHO), ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... insulin resistance and high blood pressure begin as early ... measured obesity, insulin resistance, blood pressure and cholesterol levels ... the young people were 13 and again when they ... mass index (BMI) calculation. BMI is the person's weight ...
... is being tested against cervical cancer. Human papilloma virus ... but not everyone with the virus develops the cancer. ... and causes 300,000 deaths. If it is diagnosed and ... survival rate. // ,Doctors at Britain's Cancer ...
... body to the ageing process and may increase the ... and diabetes, researchers have found. ,These days, the average ... more developed countries has decreased from nine hours to ... increased demands of work and more leisure activities. ...
... who work nightshifts are more prone to develop breast cancer. ... worked during the nights for up to three years were ... did not work at night. ,And the risk increased to ... three years. ,The results of the study, carried ...
... Women who have irregular or very long menstrual cycles ... such menstrual abnormalities needn't panic because the risk can ... exercise and weight control. // ,Menstrual cycles ... be markers for some sort of underlying metabolic abnormality. ...
... study, cycling has shown a beneficial effect in treating sexual ... produce sexual dysfunction in men because blood flow is restricted, ... an erection. The problem is that many of these men ... medication for heart failure. ,Researchers in France reported ...
Cached Medicine News:Health News:Heart disease starts early 2Health News:Deprived sleep leads to ageing 2
... an elastic belt to help lift the weight ... Apron features all around protection to cover you ... wearing and removing a breeze. ,For additional back ... - they reduce pressure on the vertebrae and ...
... a 2 adjustable belt buckle. You adjust once ... Apron off your shoulders. And now theres our ... female anatomy. ,For additional back support try one ... pressure on the vertebrae and help lift the ...
StelKast's Proven™ Knee System is a long term high quality solution based on a clinically proven and successful design....
... TC-PLUS Solution tricompartmental total knee prosthesis stems ... arthroplasty. State-of-the-art design and manufacturing technologies have ... biomechanical function as well as a favorable ... insert to keep wear to a minimum. ...
Medicine Products: